{"ticker": {"uuid": "94edcefe-abec-46ad-b6ae-8b911d3792ac", "symbol": "CING", "name": "Cingulate Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cingulate Inc. Files 8-K with SEC: Key Corporate Details, Emerging Growth Status, and Nasdaq Listing Information", "summary": "Cingulate Inc. announced key outcomes from its 2026 Annual Meeting, including the approval of an amendment to its 2021 Omnibus Equity Incentive Plan to increase authorized shares by 625,000, bringing the total to 2,221,126. Shareholders also ratified KPMG LLP as the independent a", "url": "https://www.minichart.com.sg/2026/07/14/cingulate-inc-files-8-k-with-sec-key-corporate-details-emerging-growth-status-and-nasdaq-listing-information/", "source_name": "Minichart", "published_at": "2026-07-14T15:06:47", "published_display": "14 Jul 2026 15:06", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Cingulate Inc. Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOTGtvZ01oM2hnOGhNMkJWTTIzTjBzaFVpQU0xcC1iZGNmd1ViWnpEV2h6empPQlRUdWlSS0I1UUU2M0U3d1FaNjJ4cDhHU0lObTI1cWVObWh1RWc2Q0hOUFA5dHozaXNEX1hsMUdxN1NHZms2YURvNUpkRmR0aUdENzJWbVE1SW53cU5SMWlJMTl6SFFHOXJlN0Y3VHdKb09zNndJbQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T12:00:41+00:00", "published_display": "14 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cingulate (CING) Proxy filing Summary", "summary": "Cingulate Inc. (CING) has released a proxy filing summary detailing the key proposals for its Annual Meeting scheduled for July 9, 2026. Shareholders will vote on the election of Jeff Hargroves as a Class II director, the ratification of KPMG LLP as the independent auditor, and a", "url": "https://quartr.com/events/cingulate-inc-cing-proxy-filing_FPWr8P0z", "source_name": "Quartr", "published_at": "2026-07-08T15:11:42", "published_display": "08 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cingulate Inc. \u2013 NASDAQ:CING", "summary": "This article briefly mentions the enterprise value to revenue forward for Cingulate Inc. (NASDAQ: CING). It appears to be an excerpt from a financial data platform, likely TradingView, providing financial oversight for the company. The content focuses on the stock's financial met", "url": "https://www.tradingview.com/symbols/NASDAQ-CING/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T09:12:33", "published_display": "05 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cingulate Inc. \u2013 NASDAQ:CING", "summary": "This article displays the \"Price to sales forward\" metric for Cingulate Inc. (NASDAQ: CING). The content is primarily a data placeholder within a financial platform, showing the company's ticker, market, and a period value for this specific financial ratio. No detailed analysis o", "url": "https://www.tradingview.com/symbols/NASDAQ-CING/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T09:41:04", "published_display": "04 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cingulate Inc. \u2013 NASDAQ:CING", "summary": "The article provides a financial data point for Cingulate Inc. (NASDAQ: CING), specifically mentioning its \"Price to book forward.\" It indicates the company's market and financial status, noting that the market was closed with no trades at the time of publication. The content als", "url": "https://www.tradingview.com/symbols/NASDAQ-CING/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T00:40:05", "published_display": "04 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E\u00ae", "summary": "Cingulate Inc. announced its inclusion in the Russell 3000E\u00ae Index, a significant achievement expected to enhance visibility among institutional investors and market awareness. CEO Shane Schaffer stated this inclusion reinforces the company's commitment to long-term growth as it ", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321301/0/en/cingulate-inc-nasdaq-cing-added-to-russell-3000e.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T12:09:52", "published_display": "03 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cingulate Inc For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing for Cingulate Inc. on July 2. It is a brief announcement from Investing.com and provides no further details beyond the filing date. The surrounding content consists of various market data, news headlines, and navigational elements typical o", "url": "https://uk.investing.com/news/stock-market-news/form-4-cingulate-inc-for-2-july-93CH-4755943", "source_name": "Investing.com UK", "published_at": "2026-07-02T22:13:01", "published_display": "02 Jul 2026 22:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate (CING) EVP and CSO Raul Silva receives grant of 3,885 stock options", "summary": "Cingulate Inc.'s EVP and CSO, Raul R. Silva, was granted 3,885 stock options at an exercise price of $5.47 per share, as reported in a recent Form 4 filing. These options, which expire in 2036, are part of his compensation agreement and do not represent a market purchase or sale ", "url": "https://www.stocktitan.net/sec-filings/CING/form-4-cingulate-inc-insider-trading-activity-92afd9104916.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:39", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Index addition puts Cingulate (NASDAQ: CING) into the Russell 3000E", "summary": "Cingulate Inc. (NASDAQ: CING) announced its inclusion in the Russell 3000E Index, a significant milestone expected to boost its visibility among institutional investors. Concurrently, the biopharmaceutical company extended its Chief Medical Officer Matthew N. Brams' employment tr", "url": "https://www.stocktitan.net/sec-filings/CING/8-k-cingulate-inc-reports-material-event-b84e8ca2b52a.html", "source_name": "Stock Titan", "published_at": "2026-07-02T13:09:39", "published_display": "02 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate joins Russell 3000E, boosting its profile with institutions", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQUS02M19QMEJxaGlaYmRkSjloMC11eF9LMC02TUlRZUprZmlKcG9rUS1SRzExMmlfSWFpYXZ2MThSVzNuRk80VjdHeEI2OWtyaHhSbXFIYjc2bXI3dElvZlhqZVBwTEVhcnhTalV2OVhaX3NoNTB1Ny1QblFTY0lCX0xubVFmbk1vTGJ4WXRyTzFBSGY2NFVnZG43aGNuZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate, Inc. Warrant 2021-03.12.26 on Cingulate Financial Disclosures & SEC Filings", "summary": "This article provides access to Cingulate Inc.'s SEC filings and other financial documents, including quarterly and annual earnings reports and corporate presentations, ranging from 2022 to the first quarter of 2026. Key disclosures highlight the company's progress with its CTX-1", "url": "https://www.tradingview.com/symbols/NASDAQ-CINGW/documents/", "source_name": "TradingView", "published_at": "2026-07-02T07:41:20", "published_display": "02 Jul 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Growth Benchmark Index", "summary": "Cingulate Inc. (NasdaqCM: CING) has been added to the Russell Microcap Growth Benchmark Index, a significant development for the biopharmaceutical company. This inclusion reflects the company's growth trajectory and its focus on developing innovative therapies for conditions like", "url": "https://www.marketscreener.com/news/cingulate-inc-nasdaqcm-cing-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08bf725", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:41:46", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CING Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Cingulate Inc. (CING) stock, based on analyst opinions. It details the company's current stock price, recent performance, market capitalization, and upcoming earnings report. The piece also addresses frequently asked questions", "url": "https://www.tradingview.com/symbols/NASDAQ-CING/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:50", "published_display": "26 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate, Inc. Actuals & Estimates (NASDAQ:CING)", "summary": "This article provides an overview of Cingulate Inc. (NASDAQ: CING) stock, presenting its current price, historical performance, analysts' forecasts, and volatility. It also details the company's financial data, including market capitalization, recent earnings, revenue, and future", "url": "https://www.tradingview.com/symbols/NASDAQ-CING/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:11:20", "published_display": "26 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc (CINGW) Institutional Confidence", "summary": "This article focuses on the institutional confidence in Cingulate Inc (CINGW), detailing changes in institutional shareholding. It lists several institutional investors and their holdings, noting significant decreases from firms like Citadel Advisors LLC and Armistice Capital LLC", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cingw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:41", "published_display": "18 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Cingulate Inc (CING) stock performance and its history of dividends and stock splits. CING has not distributed any dividends over the past five years. However, the company has undergone multiple merger-related stock splits, including 12-for-1 ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cing/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:59", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301", "summary": "Cingulate Inc. announced the issuance of its first U.S. patent for CTx-1301, its lead ADHD asset, covering the formulation and method of use through December 2042. This patent strengthens the company's intellectual property portfolio for its Precision Timed Release\u2122 (PTR\u2122) drug d", "url": "https://markets.businessinsider.com/news/stocks/cingulate-issued-first-u-s-patent-for-lead-adhd-asset-ctx-1301-1036252775", "source_name": "markets.businessinsider.com", "published_at": "2026-06-16T20:11:21", "published_display": "16 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US patent extends Cingulate (NASDAQ: CING) CTx-1301 ADHD exclusivity", "summary": "Cingulate Inc. announced the issuance of a new U.S. Patent No. 12,653,791 for its lead ADHD therapeutic candidate, CTx-1301, protecting its formulation and method of use through December 2042. This patent strengthens Cingulate's intellectual property for its Precision Timed Relea", "url": "https://www.stocktitan.net/sec-filings/CING/8-k-cingulate-inc-reports-material-event-05a1134e3696.html", "source_name": "Stock Titan", "published_at": "2026-06-16T12:09:14", "published_display": "16 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate issued U.S. patent for CTx-1301, exclusivity extended into Dec 2042", "summary": "Cingulate has been granted a U.S. patent for CTx-1301, its lead ADHD asset, extending its protection through December 2042. This patent covers the formulation and method of use for its trimodal Precision Timed Release tablet technology. This marks the company's first owned U.S. p", "url": "https://www.tradingview.com/news/tradingview:0987c12479266:0-cingulate-issued-u-s-patent-for-ctx-1301-exclusivity-extended-into-dec-2042/", "source_name": "TradingView", "published_at": "2026-06-16T12:09:14", "published_display": "16 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New once-daily ADHD pill design gets U.S. patent, protecting Cingulate\u2019s CTx-1301 to 2042", "summary": "Cingulate Inc. has received its first U.S. patent for its lead ADHD drug candidate, CTx-1301, extending protection for its unique \"Trimodal, Precision-Timed Pulsatile Release Tablet\" until December 2042. This patent covers composition-of-matter, formulation, structural, and metho", "url": "https://www.stocktitan.net/news/CING/cingulate-issued-first-u-s-patent-for-lead-adhd-asset-c-tx-bb7qvpfbgmpg.html", "source_name": "Stock Titan", "published_at": "2026-06-16T12:09:14", "published_display": "16 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate director Hargroves buys $490,271 of common stock", "summary": "Cingulate Inc. director Thomas Jeffrey Hargroves, through Hargroves Family Investments, LLC, purchased 97,276 shares of common stock for $490,271 and 77,821 warrants in February 2026. Hargroves also received 15,000 stock options in March 2026. These transactions, part of a privat", "url": "https://www.investing.com/news/insider-trading-news/cingulate-director-hargroves-buys-490271-of-common-stock-93CH-4731836", "source_name": "Investing.com", "published_at": "2026-06-09T13:40:45", "published_display": "09 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate (CING) director-linked LLC buys shares, warrants as options granted", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPcU1uNXBmbFNpUHRkR1B6V3k5NjJKeHdDbzd6NTMyV25pbTV3TXVUVHROR3V0UnFSRXlOT1Q1OW93Mjk2ZkV4SXlMdGxqYWpid0VpQ3JycVFkUk4wU1RBLUNIUHh5djZTYVRwclMzazVRTzBaQ09xbU1qX1hXLU9ReTJyYnllaG9GMThaVkF3OTROUzQ3YjR2VzBLX3VhS3RuVll4RkFvaTBWU3M?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26", "summary": "Stonegate Capital Partners updated its coverage on Cingulate Inc. after the FDA issued a Complete Response Letter for CTx-1301 due to CMC information requests, not clinical safety/efficacy issues. The firm believes the delay is a timing issue rather than a product viability conce", "url": "https://www.newsfilecorp.com/release/300273/Stonegate-Capital-Partners-Updates-Coverage-on-Cingulate-Inc.-CING-1Q26", "source_name": "TMX Newsfile", "published_at": "2026-06-04T21:10:04", "published_display": "04 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA focuses on manufacturing for Cingulate CTx-1301, not safety", "summary": "Stonegate Capital Partners updated its coverage on Cingulate (NASDAQ:CING) after the FDA issued a Complete Response Letter (CRL) for CTx-1301, focusing solely on manufacturing information requests rather than clinical safety or efficacy concerns. Cingulate management believes its", "url": "https://www.stocktitan.net/news/CING/stonegate-capital-partners-updates-coverage-on-cingulate-inc-cing-70g76ldjvvje.html", "source_name": "Stock Titan", "published_at": "2026-06-04T21:10:04", "published_display": "04 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301", "summary": "The FDA issued a Complete Response Letter (CRL) for Cingulate Inc.'s New Drug Application (NDA) for CTx-1301, an investigational ADHD treatment. The CRL focused solely on Chemistry, Manufacturing, and Controls (CMC) documentation and did not raise concerns about the drug's clinic", "url": "https://www.ajmc.com/view/fda-issues-complete-response-letter-for-cingulate-s-once-daily-adhd-drug-ctx-1301", "source_name": "AJMC", "published_at": "2026-06-03T15:08:46", "published_display": "03 Jun 2026 15:08", "sentiment": "negative", "sentiment_pct": 36, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Receives Complete Response Letter from FDA for CTx-1301", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cingulate-receives-complete-response-letter-120000413.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T12:00:00+00:00", "published_display": "02 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate ADHD drug faces FDA data request, no safety concerns cited", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOYm9TU1FsY3NXZTN6V3hvbDlmRXo3TFRtSTRFeDdtTUhZb3NTejZaZzRZaUZhNFkwalNzUlk0TDF1b3hmd3NCLUpEX1ZmaHAtQ3NKZlMtUWV6SG9CRUlUenR3VnhocVhBTGpYeXd2dWgxUWEwbTZUeHRXVzJ4TjUxQ3FabTgxRzI2Z3R3MjJIZnZoaGcwelFtWVdQT2hOSUI0WTdlZ0ItVkdiVlIwcjQyZFZBdkFQUmM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA sends CRL on Cingulate (NASDAQ: CING) ADHD drug CTx-1301", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNTWZWdFNYSTBPbV8zR2FSeWxmSDV0dmM0QThycXlEbGJkMGZkeGhGQU55ZHhSRVJQUjlCeVYzX21TNWNMczF2MkI0VGd6RHJVdXc5cTNqRTNRQ2x5OXd1SmpUUk10UmJRLU00RHhxVXlUOWpZdGZsZVVpSnVZeEN6dTI5eC1lVURjUXFmT2F1czFMTTdkRjZObGEzcU5mamQwWVBwaA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA declines to approve Cingulate's ADHD treatment over manufacturing issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOSGVNN28xVEZqQVpLS0FCT0o0NllXb2tmQ0Z1Z0Fkay1rN1RJNWNDbTd2YV9SbWFjUjVWaXI2WmtuSndWb2lsQmJiOVVEZjdIXzdLN0RRZXp6amNiWHdicnQ3Z2Q3bVZ6Z3RjZm9OSUxTU1ltYk9RazR2MDhBNE1DUVpMWEs1RndxRzZTQkxLd3lDTEd2STlKcWpHWklBN2NmdWk2WWpiMkJENXMxa2hSeHNTVFg0YXM?oc=5", "source_name": "Reuters", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate stock reaffirmed at Buy by H.C. Wainwright ahead of FDA decision", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNWVlxUy1hQnFSamhJZ2VFQTJPczBURmNvaUQ4d0N6TERULVRSR3FSd291WnVsNlJDX0pYZTlyRHFydThUdF9IUHF3MzIwVWNOOXVpQ0JxTFBYWFhFZXNsMU9KZHhRSEl6bV9vMW9zZEktZGstYnUtVGlOcjlBX29vLUNHa0phVTZvWHBjRDdnSGhscTdTazlLb1BRY3p6ZWpOc21iUGJMajhxM2hHZGJoME1ETFYzb2RLQ3d1WVNUamRJb1gzMEw1QndJRjI?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOSm0yb25uZFVtOUhwZzk4dXNqcmlIbHNSdXNidjZIMzVNcldVV0lleTRnM01EbWRzN3JwTVA0dGdHNG9yRTdaaUVlOUJGY25oV1dyeHk3ekpuVDNxMXY1YktJcGRsMk15Wk5hcmU3cnQydE5jdGRGR3RPR1hYMHFaR0tjYUZGZkEwb2QxNklPV2pzbzZPRTNqcDFoMHFMNkhIWXVIX3FPNA?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQYzJRSlRLWWpNYXY3SnZ0anJWTEd1RHZCZXV4X2dQaVFqZzl3a0RqSVl6OW15dUZjVUxrUEk1QWlhWE1heFFmUS1oV0lRcXdHeW81aEFpUC1IRUVELXhIVEx3Q2FKNmxSU3Y1M21ib0FCalBjSVBwVURJNHdwSkw2N3JLNlN2d0RjbWFZQlItRUhIX3lqZFJN?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cingulate says its ADHD drug faces manufacturing review, not safety issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOM1ZsaVdRNk1DTmp1RkhmQkNPaFVQbkl6cWFaS2R4Y2JJZU12bmY3cmhjYW9lQkVVZWw1b1VFZUwzd2hRSjF5Sy1ERWI0S2xNTC1RTmY0SnFhRzVELVJnSW5lRVEtU0pQZlJSNFhtYUFENkFPWldKME83dWhhSTFNY2p6TVAtRXVicXdVcG5kTFdOQWlMdXp2Wkp0SWZkOEZlaWNEN2xxSExxbzJ6LWQ5S0xqQVdvUGo4T1VXeA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxONGRudi1uWlhFdEpINXh1MU95b1VqR0M5aV95el80QnVwb1VPendQTnNEaHRkbFUwUkE3emFXb2xLLUtLUVpCX0JWTUp4MnJpeURBMzFJSTFwZmZTbTdubk9uMlJRTlhUNUctNF9BQjhVTjBqNkhKZ3pHUERnQ0pKclF0ZmVJVzEtRWxjamRYYTlRdkFjZDJrdVNsTWtORW5WeGpJUWNBWWJXb01ZMVdBSUg4MmVnZw?oc=5", "source_name": "TMX Newsfile", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPUlFkOW90RTNsMUpxZVpTZUdhSDNRMnkyb0g3aVphUEpxWUlxWmVyVTBndW82LTluTDhqN0wyTVZqVmtHTzlmWHhReDllSmszZmd6bkxSRnc2MjkxLUFxV2F3NU80elRYYmgzcGQ5X2NtYnktTDI3XzM1VFRKSDNKNGIyeEFlNmcydUE?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why did Cingulate stock skyrocket today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPbnFlN2FJZi1lSHc5WGZ2b25VT04wZDgydnRKWmRORGxUZjlvSG5wMUlHTkJONW5NUl82c09Pa0syQ0ZjRUkxeGVvQVAzQkxmSkxjWFhtUHhaMjJNSVRsYjlHUUFMODl0VVFhZHViY0NEMk5Tdk8yNE5qMnVqT2MwQw?oc=5", "source_name": "Invezz", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate (NASDAQ: CING) Gains FDA Acceptance of CTx-1301 NDA, Eyes ADHD Launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPNkdWRHN3aXJEZG45dFpZcS0wVmoxc3VTbUV2VE92VW0yenlnOGZMQlBmNmFXcUdxdFlKTGZfeThpTjBXQ2F2TFZTVnRwX0x0NEgzbnlBVENxSXIySGNISkdCNlRKc2RFdzFRa05QNDB4S0wyeHBOQXFFU0ZJeHhUcDBGem9mRVl2c3JHS0FlNGFNUlFlUXg1TlVkQndqdmVlcEx0c1BFcDFLRnl6cjk5NVZnMjY0V01NdzN4NA?oc=5", "source_name": "Stock Titan", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdmw4aDJvVEdJRnBndnZRU2lHUFZDU1c3SVJaUlE4X3E1UjItaFVJQlVyZWNjRHBNU0RNQTZHa2NLTGY0Z3lscUhTcGRRS0g4eXJOUnFuNnhPYXZBNkQ3MDlNNl9aMk1sS2xYcnBVS2I0Z1JBTTRreGt0al9kbDBpc2RISFlOclh1?oc=5", "source_name": "Market source", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate (NASDAQ: CING) appoints CCO to drive CTx-1301 launch prep amid May 2026 PDUFA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcWNkU2EtOWNCSFdxeE9hVmJYaTBaYkZHVHA5ZHFmMVZSMlM0YlVMYnNQa01YZnFlUWZwVXhzQkVhak5pVlpaTDdOcW1hV0ZyWE1faE9fcVJtYUV1WDVab3dBSWpCUEdrTVFpWTVHWkdTeWxHRVlNUE8zcU1PSlQzSEY1MWlqa0ZoRHJwV3lDZUNRUC1CQUNlSWhiUmRSMklNRklDb3ZQNTEtMDhfLW1KQVNNV3plMU5p?oc=5", "source_name": "Stock Titan", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CING SEC Filings - Cingulate Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE05eXhaakNlMlRrMzY0SHZRS3J0TERXSDJ5TlpJRHRjekFsTmhZZlVZT0h0MEQxLUZJU3N3Wlk0VDhNRlVmV0k2NFdPbWNwRVlVakI0OHNucw?oc=5", "source_name": "Stock Titan", "published_at": "2025-09-25T23:45:21+00:00", "published_display": "25 Sep 2025 23:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cingulate Inc. Files 8-K with SEC: Key Corporate Details, Emerging Growth Status, and Nasdaq Listing Information", "summary": "Cingulate Inc. announced key outcomes from its 2026 Annual Meeting, including the approval of an amendment to its 2021 Omnibus Equity Incentive Plan to increase authorized shares by 625,000, bringing the total to 2,221,126. Shareholders also ratified KPMG LLP as the independent a", "url": "https://www.minichart.com.sg/2026/07/14/cingulate-inc-files-8-k-with-sec-key-corporate-details-emerging-growth-status-and-nasdaq-listing-information/", "source_name": "Minichart", "published_at": "2026-07-14T15:06:47", "published_display": "14 Jul 2026 15:06", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Cingulate Inc. Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOTGtvZ01oM2hnOGhNMkJWTTIzTjBzaFVpQU0xcC1iZGNmd1ViWnpEV2h6empPQlRUdWlSS0I1UUU2M0U3d1FaNjJ4cDhHU0lObTI1cWVObWh1RWc2Q0hOUFA5dHozaXNEX1hsMUdxN1NHZms2YURvNUpkRmR0aUdENzJWbVE1SW53cU5SMWlJMTl6SFFHOXJlN0Y3VHdKb09zNndJbQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T12:00:41+00:00", "published_display": "14 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate (CING) Proxy filing Summary", "summary": "Cingulate Inc. (CING) has released a proxy filing summary detailing the key proposals for its Annual Meeting scheduled for July 9, 2026. Shareholders will vote on the election of Jeff Hargroves as a Class II director, the ratification of KPMG LLP as the independent auditor, and a", "url": "https://quartr.com/events/cingulate-inc-cing-proxy-filing_FPWr8P0z", "source_name": "Quartr", "published_at": "2026-07-08T15:11:42", "published_display": "08 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cingulate Inc. \u2013 NASDAQ:CING", "summary": "This article briefly mentions the enterprise value to revenue forward for Cingulate Inc. (NASDAQ: CING). It appears to be an excerpt from a financial data platform, likely TradingView, providing financial oversight for the company. The content focuses on the stock's financial met", "url": "https://www.tradingview.com/symbols/NASDAQ-CING/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T09:12:33", "published_display": "05 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cingulate Inc. \u2013 NASDAQ:CING", "summary": "This article displays the \"Price to sales forward\" metric for Cingulate Inc. (NASDAQ: CING). The content is primarily a data placeholder within a financial platform, showing the company's ticker, market, and a period value for this specific financial ratio. No detailed analysis o", "url": "https://www.tradingview.com/symbols/NASDAQ-CING/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T09:41:04", "published_display": "04 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cingulate Inc. \u2013 NASDAQ:CING", "summary": "The article provides a financial data point for Cingulate Inc. (NASDAQ: CING), specifically mentioning its \"Price to book forward.\" It indicates the company's market and financial status, noting that the market was closed with no trades at the time of publication. The content als", "url": "https://www.tradingview.com/symbols/NASDAQ-CING/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T00:40:05", "published_display": "04 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E\u00ae", "summary": "Cingulate Inc. announced its inclusion in the Russell 3000E\u00ae Index, a significant achievement expected to enhance visibility among institutional investors and market awareness. CEO Shane Schaffer stated this inclusion reinforces the company's commitment to long-term growth as it ", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321301/0/en/cingulate-inc-nasdaq-cing-added-to-russell-3000e.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T12:09:52", "published_display": "03 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cingulate Inc For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing for Cingulate Inc. on July 2. It is a brief announcement from Investing.com and provides no further details beyond the filing date. The surrounding content consists of various market data, news headlines, and navigational elements typical o", "url": "https://uk.investing.com/news/stock-market-news/form-4-cingulate-inc-for-2-july-93CH-4755943", "source_name": "Investing.com UK", "published_at": "2026-07-02T22:13:01", "published_display": "02 Jul 2026 22:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate (CING) EVP and CSO Raul Silva receives grant of 3,885 stock options", "summary": "Cingulate Inc.'s EVP and CSO, Raul R. Silva, was granted 3,885 stock options at an exercise price of $5.47 per share, as reported in a recent Form 4 filing. These options, which expire in 2036, are part of his compensation agreement and do not represent a market purchase or sale ", "url": "https://www.stocktitan.net/sec-filings/CING/form-4-cingulate-inc-insider-trading-activity-92afd9104916.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:39", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Index addition puts Cingulate (NASDAQ: CING) into the Russell 3000E", "summary": "Cingulate Inc. (NASDAQ: CING) announced its inclusion in the Russell 3000E Index, a significant milestone expected to boost its visibility among institutional investors. Concurrently, the biopharmaceutical company extended its Chief Medical Officer Matthew N. Brams' employment tr", "url": "https://www.stocktitan.net/sec-filings/CING/8-k-cingulate-inc-reports-material-event-b84e8ca2b52a.html", "source_name": "Stock Titan", "published_at": "2026-07-02T13:09:39", "published_display": "02 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate joins Russell 3000E, boosting its profile with institutions", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQUS02M19QMEJxaGlaYmRkSjloMC11eF9LMC02TUlRZUprZmlKcG9rUS1SRzExMmlfSWFpYXZ2MThSVzNuRk80VjdHeEI2OWtyaHhSbXFIYjc2bXI3dElvZlhqZVBwTEVhcnhTalV2OVhaX3NoNTB1Ny1QblFTY0lCX0xubVFmbk1vTGJ4WXRyTzFBSGY2NFVnZG43aGNuZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate, Inc. Warrant 2021-03.12.26 on Cingulate Financial Disclosures & SEC Filings", "summary": "This article provides access to Cingulate Inc.'s SEC filings and other financial documents, including quarterly and annual earnings reports and corporate presentations, ranging from 2022 to the first quarter of 2026. Key disclosures highlight the company's progress with its CTX-1", "url": "https://www.tradingview.com/symbols/NASDAQ-CINGW/documents/", "source_name": "TradingView", "published_at": "2026-07-02T07:41:20", "published_display": "02 Jul 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Growth Benchmark Index", "summary": "Cingulate Inc. (NasdaqCM: CING) has been added to the Russell Microcap Growth Benchmark Index, a significant development for the biopharmaceutical company. This inclusion reflects the company's growth trajectory and its focus on developing innovative therapies for conditions like", "url": "https://www.marketscreener.com/news/cingulate-inc-nasdaqcm-cing-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08bf725", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:41:46", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CING Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Cingulate Inc. (CING) stock, based on analyst opinions. It details the company's current stock price, recent performance, market capitalization, and upcoming earnings report. The piece also addresses frequently asked questions", "url": "https://www.tradingview.com/symbols/NASDAQ-CING/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:50", "published_display": "26 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate, Inc. Actuals & Estimates (NASDAQ:CING)", "summary": "This article provides an overview of Cingulate Inc. (NASDAQ: CING) stock, presenting its current price, historical performance, analysts' forecasts, and volatility. It also details the company's financial data, including market capitalization, recent earnings, revenue, and future", "url": "https://www.tradingview.com/symbols/NASDAQ-CING/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:11:20", "published_display": "26 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc (CINGW) Institutional Confidence", "summary": "This article focuses on the institutional confidence in Cingulate Inc (CINGW), detailing changes in institutional shareholding. It lists several institutional investors and their holdings, noting significant decreases from firms like Citadel Advisors LLC and Armistice Capital LLC", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cingw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:41", "published_display": "18 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Cingulate Inc (CING) stock performance and its history of dividends and stock splits. CING has not distributed any dividends over the past five years. However, the company has undergone multiple merger-related stock splits, including 12-for-1 ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cing/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:59", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301", "summary": "Cingulate Inc. announced the issuance of its first U.S. patent for CTx-1301, its lead ADHD asset, covering the formulation and method of use through December 2042. This patent strengthens the company's intellectual property portfolio for its Precision Timed Release\u2122 (PTR\u2122) drug d", "url": "https://markets.businessinsider.com/news/stocks/cingulate-issued-first-u-s-patent-for-lead-adhd-asset-ctx-1301-1036252775", "source_name": "markets.businessinsider.com", "published_at": "2026-06-16T20:11:21", "published_display": "16 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US patent extends Cingulate (NASDAQ: CING) CTx-1301 ADHD exclusivity", "summary": "Cingulate Inc. announced the issuance of a new U.S. Patent No. 12,653,791 for its lead ADHD therapeutic candidate, CTx-1301, protecting its formulation and method of use through December 2042. This patent strengthens Cingulate's intellectual property for its Precision Timed Relea", "url": "https://www.stocktitan.net/sec-filings/CING/8-k-cingulate-inc-reports-material-event-05a1134e3696.html", "source_name": "Stock Titan", "published_at": "2026-06-16T12:09:14", "published_display": "16 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate issued U.S. patent for CTx-1301, exclusivity extended into Dec 2042", "summary": "Cingulate has been granted a U.S. patent for CTx-1301, its lead ADHD asset, extending its protection through December 2042. This patent covers the formulation and method of use for its trimodal Precision Timed Release tablet technology. This marks the company's first owned U.S. p", "url": "https://www.tradingview.com/news/tradingview:0987c12479266:0-cingulate-issued-u-s-patent-for-ctx-1301-exclusivity-extended-into-dec-2042/", "source_name": "TradingView", "published_at": "2026-06-16T12:09:14", "published_display": "16 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New once-daily ADHD pill design gets U.S. patent, protecting Cingulate\u2019s CTx-1301 to 2042", "summary": "Cingulate Inc. has received its first U.S. patent for its lead ADHD drug candidate, CTx-1301, extending protection for its unique \"Trimodal, Precision-Timed Pulsatile Release Tablet\" until December 2042. This patent covers composition-of-matter, formulation, structural, and metho", "url": "https://www.stocktitan.net/news/CING/cingulate-issued-first-u-s-patent-for-lead-adhd-asset-c-tx-bb7qvpfbgmpg.html", "source_name": "Stock Titan", "published_at": "2026-06-16T12:09:14", "published_display": "16 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate director Hargroves buys $490,271 of common stock", "summary": "Cingulate Inc. director Thomas Jeffrey Hargroves, through Hargroves Family Investments, LLC, purchased 97,276 shares of common stock for $490,271 and 77,821 warrants in February 2026. Hargroves also received 15,000 stock options in March 2026. These transactions, part of a privat", "url": "https://www.investing.com/news/insider-trading-news/cingulate-director-hargroves-buys-490271-of-common-stock-93CH-4731836", "source_name": "Investing.com", "published_at": "2026-06-09T13:40:45", "published_display": "09 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate (CING) director-linked LLC buys shares, warrants as options granted", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPcU1uNXBmbFNpUHRkR1B6V3k5NjJKeHdDbzd6NTMyV25pbTV3TXVUVHROR3V0UnFSRXlOT1Q1OW93Mjk2ZkV4SXlMdGxqYWpid0VpQ3JycVFkUk4wU1RBLUNIUHh5djZTYVRwclMzazVRTzBaQ09xbU1qX1hXLU9ReTJyYnllaG9GMThaVkF3OTROUzQ3YjR2VzBLX3VhS3RuVll4RkFvaTBWU3M?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26", "summary": "Stonegate Capital Partners updated its coverage on Cingulate Inc. after the FDA issued a Complete Response Letter for CTx-1301 due to CMC information requests, not clinical safety/efficacy issues. The firm believes the delay is a timing issue rather than a product viability conce", "url": "https://www.newsfilecorp.com/release/300273/Stonegate-Capital-Partners-Updates-Coverage-on-Cingulate-Inc.-CING-1Q26", "source_name": "TMX Newsfile", "published_at": "2026-06-04T21:10:04", "published_display": "04 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA focuses on manufacturing for Cingulate CTx-1301, not safety", "summary": "Stonegate Capital Partners updated its coverage on Cingulate (NASDAQ:CING) after the FDA issued a Complete Response Letter (CRL) for CTx-1301, focusing solely on manufacturing information requests rather than clinical safety or efficacy concerns. Cingulate management believes its", "url": "https://www.stocktitan.net/news/CING/stonegate-capital-partners-updates-coverage-on-cingulate-inc-cing-70g76ldjvvje.html", "source_name": "Stock Titan", "published_at": "2026-06-04T21:10:04", "published_display": "04 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301", "summary": "The FDA issued a Complete Response Letter (CRL) for Cingulate Inc.'s New Drug Application (NDA) for CTx-1301, an investigational ADHD treatment. The CRL focused solely on Chemistry, Manufacturing, and Controls (CMC) documentation and did not raise concerns about the drug's clinic", "url": "https://www.ajmc.com/view/fda-issues-complete-response-letter-for-cingulate-s-once-daily-adhd-drug-ctx-1301", "source_name": "AJMC", "published_at": "2026-06-03T15:08:46", "published_display": "03 Jun 2026 15:08", "sentiment": "negative", "sentiment_pct": 36, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Receives Complete Response Letter from FDA for CTx-1301", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cingulate-receives-complete-response-letter-120000413.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T12:00:00+00:00", "published_display": "02 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate ADHD drug faces FDA data request, no safety concerns cited", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOYm9TU1FsY3NXZTN6V3hvbDlmRXo3TFRtSTRFeDdtTUhZb3NTejZaZzRZaUZhNFkwalNzUlk0TDF1b3hmd3NCLUpEX1ZmaHAtQ3NKZlMtUWV6SG9CRUlUenR3VnhocVhBTGpYeXd2dWgxUWEwbTZUeHRXVzJ4TjUxQ3FabTgxRzI2Z3R3MjJIZnZoaGcwelFtWVdQT2hOSUI0WTdlZ0ItVkdiVlIwcjQyZFZBdkFQUmM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA sends CRL on Cingulate (NASDAQ: CING) ADHD drug CTx-1301", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNTWZWdFNYSTBPbV8zR2FSeWxmSDV0dmM0QThycXlEbGJkMGZkeGhGQU55ZHhSRVJQUjlCeVYzX21TNWNMczF2MkI0VGd6RHJVdXc5cTNqRTNRQ2x5OXd1SmpUUk10UmJRLU00RHhxVXlUOWpZdGZsZVVpSnVZeEN6dTI5eC1lVURjUXFmT2F1czFMTTdkRjZObGEzcU5mamQwWVBwaA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA declines to approve Cingulate's ADHD treatment over manufacturing issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOSGVNN28xVEZqQVpLS0FCT0o0NllXb2tmQ0Z1Z0Fkay1rN1RJNWNDbTd2YV9SbWFjUjVWaXI2WmtuSndWb2lsQmJiOVVEZjdIXzdLN0RRZXp6amNiWHdicnQ3Z2Q3bVZ6Z3RjZm9OSUxTU1ltYk9RazR2MDhBNE1DUVpMWEs1RndxRzZTQkxLd3lDTEd2STlKcWpHWklBN2NmdWk2WWpiMkJENXMxa2hSeHNTVFg0YXM?oc=5", "source_name": "Reuters", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate stock reaffirmed at Buy by H.C. Wainwright ahead of FDA decision", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNWVlxUy1hQnFSamhJZ2VFQTJPczBURmNvaUQ4d0N6TERULVRSR3FSd291WnVsNlJDX0pYZTlyRHFydThUdF9IUHF3MzIwVWNOOXVpQ0JxTFBYWFhFZXNsMU9KZHhRSEl6bV9vMW9zZEktZGstYnUtVGlOcjlBX29vLUNHa0phVTZvWHBjRDdnSGhscTdTazlLb1BRY3p6ZWpOc21iUGJMajhxM2hHZGJoME1ETFYzb2RLQ3d1WVNUamRJb1gzMEw1QndJRjI?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOSm0yb25uZFVtOUhwZzk4dXNqcmlIbHNSdXNidjZIMzVNcldVV0lleTRnM01EbWRzN3JwTVA0dGdHNG9yRTdaaUVlOUJGY25oV1dyeHk3ekpuVDNxMXY1YktJcGRsMk15Wk5hcmU3cnQydE5jdGRGR3RPR1hYMHFaR0tjYUZGZkEwb2QxNklPV2pzbzZPRTNqcDFoMHFMNkhIWXVIX3FPNA?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQYzJRSlRLWWpNYXY3SnZ0anJWTEd1RHZCZXV4X2dQaVFqZzl3a0RqSVl6OW15dUZjVUxrUEk1QWlhWE1heFFmUS1oV0lRcXdHeW81aEFpUC1IRUVELXhIVEx3Q2FKNmxSU3Y1M21ib0FCalBjSVBwVURJNHdwSkw2N3JLNlN2d0RjbWFZQlItRUhIX3lqZFJN?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate says its ADHD drug faces manufacturing review, not safety issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOM1ZsaVdRNk1DTmp1RkhmQkNPaFVQbkl6cWFaS2R4Y2JJZU12bmY3cmhjYW9lQkVVZWw1b1VFZUwzd2hRSjF5Sy1ERWI0S2xNTC1RTmY0SnFhRzVELVJnSW5lRVEtU0pQZlJSNFhtYUFENkFPWldKME83dWhhSTFNY2p6TVAtRXVicXdVcG5kTFdOQWlMdXp2Wkp0SWZkOEZlaWNEN2xxSExxbzJ6LWQ5S0xqQVdvUGo4T1VXeA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxONGRudi1uWlhFdEpINXh1MU95b1VqR0M5aV95el80QnVwb1VPendQTnNEaHRkbFUwUkE3emFXb2xLLUtLUVpCX0JWTUp4MnJpeURBMzFJSTFwZmZTbTdubk9uMlJRTlhUNUctNF9BQjhVTjBqNkhKZ3pHUERnQ0pKclF0ZmVJVzEtRWxjamRYYTlRdkFjZDJrdVNsTWtORW5WeGpJUWNBWWJXb01ZMVdBSUg4MmVnZw?oc=5", "source_name": "TMX Newsfile", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPUlFkOW90RTNsMUpxZVpTZUdhSDNRMnkyb0g3aVphUEpxWUlxWmVyVTBndW82LTluTDhqN0wyTVZqVmtHTzlmWHhReDllSmszZmd6bkxSRnc2MjkxLUFxV2F3NU80elRYYmgzcGQ5X2NtYnktTDI3XzM1VFRKSDNKNGIyeEFlNmcydUE?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why did Cingulate stock skyrocket today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPbnFlN2FJZi1lSHc5WGZ2b25VT04wZDgydnRKWmRORGxUZjlvSG5wMUlHTkJONW5NUl82c09Pa0syQ0ZjRUkxeGVvQVAzQkxmSkxjWFhtUHhaMjJNSVRsYjlHUUFMODl0VVFhZHViY0NEMk5Tdk8yNE5qMnVqT2MwQw?oc=5", "source_name": "Invezz", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate (NASDAQ: CING) Gains FDA Acceptance of CTx-1301 NDA, Eyes ADHD Launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPNkdWRHN3aXJEZG45dFpZcS0wVmoxc3VTbUV2VE92VW0yenlnOGZMQlBmNmFXcUdxdFlKTGZfeThpTjBXQ2F2TFZTVnRwX0x0NEgzbnlBVENxSXIySGNISkdCNlRKc2RFdzFRa05QNDB4S0wyeHBOQXFFU0ZJeHhUcDBGem9mRVl2c3JHS0FlNGFNUlFlUXg1TlVkQndqdmVlcEx0c1BFcDFLRnl6cjk5NVZnMjY0V01NdzN4NA?oc=5", "source_name": "Stock Titan", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdmw4aDJvVEdJRnBndnZRU2lHUFZDU1c3SVJaUlE4X3E1UjItaFVJQlVyZWNjRHBNU0RNQTZHa2NLTGY0Z3lscUhTcGRRS0g4eXJOUnFuNnhPYXZBNkQ3MDlNNl9aMk1sS2xYcnBVS2I0Z1JBTTRreGt0al9kbDBpc2RISFlOclh1?oc=5", "source_name": "Market source", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cingulate (NASDAQ: CING) appoints CCO to drive CTx-1301 launch prep amid May 2026 PDUFA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcWNkU2EtOWNCSFdxeE9hVmJYaTBaYkZHVHA5ZHFmMVZSMlM0YlVMYnNQa01YZnFlUWZwVXhzQkVhak5pVlpaTDdOcW1hV0ZyWE1faE9fcVJtYUV1WDVab3dBSWpCUEdrTVFpWTVHWkdTeWxHRVlNUE8zcU1PSlQzSEY1MWlqa0ZoRHJwV3lDZUNRUC1CQUNlSWhiUmRSMklNRklDb3ZQNTEtMDhfLW1KQVNNV3plMU5p?oc=5", "source_name": "Stock Titan", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CING SEC Filings - Cingulate Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE05eXhaakNlMlRrMzY0SHZRS3J0TERXSDJ5TlpJRHRjekFsTmhZZlVZT0h0MEQxLUZJU3N3Wlk0VDhNRlVmV0k2NFdPbWNwRVlVakI0OHNucw?oc=5", "source_name": "Stock Titan", "published_at": "2025-09-25T23:45:21+00:00", "published_display": "25 Sep 2025 23:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 50, "sentiment_summary": {"positive": 13, "negative": 3, "neutral": 34, "score": 55, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 17.4, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 4.91, "latest_week": "2026-07-10", "one_week_move": -8.7, "four_week_move": 0.6, "twelve_week_move": -9.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.712663, "market_dynamics_buy_signal": false, "relative_strength": -14.212898, "fair_value_gap": -79.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.5772, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.7% over one week, +0.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "Market source", "count": 9}, {"label": "TradingView", "count": 8}, {"label": "GlobeNewswire", "count": 2}, {"label": "TradingKey", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "TMX Newsfile", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 15}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.7% over one week, +0.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Cingulate Inc. Files 8-K with SEC: Key Corporate Details, Emerging Growth Status, and Nasdaq Listing Information"}], "updated_at": "2026-07-17T11:00:09.087903+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}